Jasper Therapeutics (JSPR) Common Equity (2019 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Common Equity of $4.2 million for Q4 2025, down 93.27% year-over-year from $61.7 million in Q4 2024, and down 64.13% quarter-over-quarter from $11.6 million in Q3 2025.
Jasper Therapeutics (JSPR) Common Equity (2019 - 2025) Analysis & Trends
Jasper Therapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $4.2 million for Q4 2025.
- In Q4 2025, Common Equity fell 93.27% year-over-year to $4.2 million; the TTM figure through Dec 2025 stood at $4.2 million (down 93.27% YoY), while the FY2025 annual figure was $4.2 million, down 93.27% from the prior year.
- Common Equity for Q4 2025 stood at $4.2 million, down from $11.6 million in the prior quarter.
- The five-year high for Common Equity was $125.2 million in Q1 2023, with the low at -$52.6 million in Q2 2021.
- The 5-year median for Common Equity is $64.9 million (2022), against an average of $55.5 million.
- Peak annual rise in Common Equity reached 406.62% in 2021, while the deepest fall reached 622.66% in 2021.
- Jasper Therapeutics' Common Equity stood at $69.5 million in 2021, then tumbled by 48.23% to $36.0 million in 2022, then jumped by 117.96% to $78.4 million in 2023, then retreated by 21.37% to $61.7 million in 2024, then plunged by 93.27% to $4.2 million in 2025.
- Business Quant data shows JSPR's Common Equity at $4.2 million in Q4 2025, $11.6 million in Q3 2025, and $23.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Jasper Therapeutics | 20.06 Mn | 20.06 Mn | - | 1.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.15 Mn |
| Sep 30, 2025 | 11.57 Mn |
| Jun 30, 2025 | 23.50 Mn |
| Mar 31, 2025 | 42.24 Mn |
| Dec 31, 2024 | 61.67 Mn |
| Sep 30, 2024 | 83.68 Mn |
| Jun 30, 2024 | 100.31 Mn |
| Mar 31, 2024 | 113.23 Mn |
| Dec 31, 2023 | 78.44 Mn |
| Sep 30, 2023 | 94.13 Mn |
| Jun 30, 2023 | 110.21 Mn |
| Mar 31, 2023 | 125.20 Mn |
| Dec 31, 2022 | 35.99 Mn |
| Sep 30, 2022 | 47.57 Mn |
| Jun 30, 2022 | 58.78 Mn |
| Mar 31, 2022 | 68.11 Mn |
| Dec 31, 2021 | 69.52 Mn |
| Sep 30, 2021 | 78.60 Mn |
| Jun 30, 2021 | -52.60 Mn |
| Mar 31, 2021 | -44.55 Mn |